TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25559915
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training three times weekly
Study: 19893122
Drug: Therapeutic education
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic education on CHF topics (general information, symptoms, dietary nutrition, medicative therapy)
Study: 11795438
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg/day) for 3 months
Study: 9501267
Drug: Phenylalanine‐complemented amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylalanine‐complemented amino acid supplement (increased blood phenylalanine concentrations to 1000-1300 mumol/L for 3 months)
Study: 1098358
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (2000 international units daily for 3 months)
Study: 20337618
Drug: ramosetron 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramosetron 0.3 mg (n = 42)
Study: 20337618
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg (n = 42)
Study: 3596789
Drug: Inclusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclusion of the beta-blocker oxprenolol
Study: 29019894
Drug: Late-course concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late-course concurrent chemoradiotherapy (CCRT)
Study: 29019894
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (SCRT)
Study: 29019894
Drug: Late-course concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late-course concurrent chemoradiotherapy (CCRT) in pT3-4 pN1-3 cM0 subgroup
Study: 29019894
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (SCRT) in pT3-4 pN1-3 cM0 subgroup
Study: 21733566
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Catumaxomab (10, 20, 50, and 100 μg)
Study: 21733566
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Catumaxomab (10 μg)
Study: 19811362
Drug: GABA-rich Chlorella
Normalized name: Chlorella emersonii extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA-rich Chlorella (20 mg as gamma-aminobutyric acid)
Study: 9754979
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 1.2 mg twice daily
Study: 7828695
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (800 micrograms.day‐1)
Study: 27521028
Drug: no laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: no laser treatment (control group)
Study: 21442808
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (Tianqi Tongjing Capsule)
Study: 16474093
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment for both humans and buffaloes in Jishan
Study: 16474093
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment for humans only in Hexi
Study: 16474093
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for buffaloes in Jishan
Study: 8495764
Drug: Danazol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (600 mg/d)
Study: 3120167
Drug: stress tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: stress tests (insulin‐induced hypoglycaemia/glucagon)
Study: 27696440
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg raltegravir (q.d.) alone
Study: 27696440
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg raltegravir co-administered with 400 mg atazanavir (q.d.)
Study: 27696440
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg atazanavir (q.d.)
Study: 22571342
Drug: MG98 125
Normalized name: MG98
DrugBank: MG98 (DB06544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG98 125 mg/m2 with Interferon-α-2β 9 MIU (continuous schedule)
Study: 22571342
Drug: MG98 200
Normalized name: MG98
DrugBank: MG98 (DB06544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG98 200 mg/m2 with Interferon-α-2β 9 MIU (intermittent schedule)
Study: 20861218
Drug: Lipid-based nutrient
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-based nutrient supplements (LNS) 43 g/d for 12 weeks
Study: 20861218
Drug: Corn-soy blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn-soy blend (CSB) 71 g/d for 12 weeks
Study: 16133554
Drug: 0.2 g
Normalized name: methionine 0.2 gram ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 g BBR three times daily for 3 months
Study: 16133554
Drug: CsA without
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA without BBR co-administration
Study: 12177103
Drug: Combined induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined induction and radiotherapy (HFEBRT at a dose of 72 Gy)
Study: 12177103
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to chemotherapy
Study: 1977258
Drug: Cyclosporin A,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A, 5 mg/kg/day for 10 days
Study: 20737165
Drug: Caffeine (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (240 mg) via chewing gum
Study: 18831749
Drug: Echinacea purpurea
Normalized name: Echinacea purpurea
DrugBank: Echinacea purpurea (DB14239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea purpurea (alcohol extract) administered for 10 days at the first sign of each common cold
Study: 18831749
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment (OMT) including cranial manipulation, with up to five visits over 3 months
Study: 11841372
Drug: 3.0% diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0% diclofenac in 2.5% hyaluronan gel for 60 days
Study: 11841372
Drug: 3.0% diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0% diclofenac in 2.5% hyaluronan gel for 30 days
Study: 11841372
Drug: Placebo (2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2.5% hyaluronan gel) for 60 days
Study: 11841372
Drug: Placebo (2.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2.5% hyaluronan gel) for 30 days
Study: 10080462
Drug: Sibrafiban (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibrafiban (oral, selective antagonist of platelet glycoprotein IIb/IIIa receptor)
Study: 7672773
Drug: Aluminium phosphate
Normalized name: Aluminium phosphate
DrugBank: Aluminium phosphate (DB14517)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminium phosphate gel (11 g five times a day)
Study: 7672773
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg once daily for 6 weeks)
Study: 7672773
Drug: Aluminium phosphate
Normalized name: Aluminium phosphate
DrugBank: Aluminium phosphate (DB14517)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aluminium phosphate gel
Study: 3966685
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate (10 mg)
Study: 30898502
Drug: Prophylactic incisional
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic incisional negative pressure wound therapy (iNPWT)
Study: 21367355
Drug: Lamotrigine (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (titrated to a maximum of 400 mg/d for 10 weeks)
Study: 15156253
Drug: Aescin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aescin and essential phospholipids (AEPL) gel
Study: 11839116
Drug: 12 group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 group sessions (twice a month)
Study: 7593457
Drug: Continuous transdermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous transdermal estradiol (50 ug/24 hrs) with periodic medroxyprogesterone (10.0 mg/day) (n = 13)
Study: 7593457
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral estradiol (2.0 mg/day) and continuous norethisterone acetate (1.0 mg/day) (n = 13)
Study: 28388994
Drug: Baseline hemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline hemoglobin <12 g/dl in women or <13 g/dl in men (anemia)
Study: 25879863
Drug: Sertraline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (75 mg/day) plus deanxit (one piece/day)
Study: 25879863
Drug: Sertraline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (75 mg/day) plus placebo (one piece/day)
Study: 21463215
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (0.3 g/kg/day, n = 51-Gln group)
Study: 15038804
Drug: Medication Alliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Alliance training program
Study: 7840516
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methotrexate followed by 5‐Fluorouracil and leucovorin rescue on day 1 (Arm A)
Study: 24961091
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of 0.5% betaxolol and 0.2% brimonidine
Study: 21421493
Drug: G‐CSF (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF (600 µg/day) for 7 consecutive days
Study: 21421493
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (medication and interventional therapy)
Study: 19266831
Drug: Ropivacaine 0.8
Normalized name: ROPivacaine 0.8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.8 mg.kg(‐1) at 1 mg.ml(‐1) (0.8 ml.kg(‐1)) in G1 group
Study: 19266831
Drug: Ropivacaine 0.8
Normalized name: ROPivacaine 0.8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.8 mg.kg(‐1) at 2 mg.ml(‐1) (0.4 ml.kg(‐1)) in G2 group
Study: 17885570
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) (n = 19)
Study: 11719029
Drug: Vaccinia melanoma
Normalized name: vaccinia virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinia melanoma oncolysate (VMO) therapy
Study: 11719029
Drug: Control vaccinia
Normalized name: vaccinia virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccinia virus (V) therapy
Study: 11719029
Drug: ECOG and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECOG and Mayo treatment arms
Study: 9593234
Drug: Preoperative high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative high-dose radiotherapy (5 x 5 Gy)
Study: 7874153
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution (C)
Study: 3606231
Drug: BSHGH (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSHGH (0.1 mg/kg/24 h)
Study: 27031181
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg daily for 28 days
Study: 23178468
Drug: Somatostatin administration
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin administration (infused 1 day before operation and continued for 7 days after surgery)
Study: 21436689
Drug: lotrafilcon B/polyhexamethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: lotrafilcon B/polyhexamethylene biguanide (PHMB)‐based multipurpose (MPS) solution (MPS‐1)
Study: 21436689
Drug: lotrafilcon B/polyquaternium‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: lotrafilcon B/polyquaternium‐1 and myristamidopropyl dimethylamine‐based solution (MPS‐2)
Study: 21436689
Drug: lotrafilcon B
Approvals — FDA: no, EMA: no, PMDA: no
Description: lotrafilcon B and another PHMB‐based solution (MPS‐3)
Study: 12941723
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg once daily for 16 weeks
Study: 10960381
Drug: Morphine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (administered via retrobulbar catheter)
Study: 8977350
Drug: Flumazenil (0.4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.4, 0.8, and 1 mg bolus injections followed by 1 mg/h infusion for three hours)
Study: 8977350
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three sequential bolus injections followed by placebo infusion)
Study: 27473050
Drug: Low tidal-volume
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal-volume ventilation (6 mL•kg(‐1) ideal body weight) with PEEP of 3 cm H2O
Study: 27473050
Drug: Conventional tidal-volume
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional tidal-volume ventilation (12 mL•kg(‐1) ideal body weight) with PEEP of 3 cm H2O
Study: 24680265
Drug: Thrombus aspiration
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombus aspiration and intracoronary tirofiban combined with nitroprusside bolus (200 µg prior to the first balloon inflation, Group C)
Study: 24680265
Drug: Thrombus aspiration
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombus aspiration and intracoronary tirofiban bolus (25 µg/kg prior to the first balloon inflation, Group B)
Study: 19144653
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Angiotensin-converting enzyme inhibitors + Angiotensin receptor blockers)
Study: 17256447
Drug: Psychotropic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic drugs (antidepressants and/or benzodiazepines)
Study: 15992236
Drug: Static magnets
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Static magnets (after excluding inadequate treatment studies)
Study: 12162471
Drug: GW433908G tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW433908G tablet
Study: 12162471
Drug: GW433908G suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW433908G suspension
Study: 12162471
Drug: GW433908G tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW433908G tablets
Study: 12162471
Drug: amprenavir capsules
Normalized name: amprenavir Oral Capsule
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: amprenavir capsules
Study: 9475647
Drug: Phosphagen HP
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphagen HP with 15.75 g x d(‐1) of HPCE pure creatine monohydrate (HP)
Study: 8751030
Drug: Homeopathic after-bite
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Homeopathic after-bite gel
Study: 8751030
Drug: Homeopathic after-bite
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Homeopathic after-bite gel vs Untreated spots
Study: 8751030
Drug: Homeopathic after-bite
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Homeopathic after-bite gel vs Placebo gel
Study: 8751030
Drug: Homeopathic after-bite
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Homeopathic after-bite gel vs No treatment (pooled data)
Study: 8751030
Drug: Homeopathic after-bite
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Homeopathic after-bite gel vs Placebo gel (pooled data)
Study: 8751030
Drug: Extent of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extent of itching after treatments
Study: 2210982
Drug: Parenteral piperacillin
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral piperacillin alone (Group B, n = 22)
Study: 2210982
Drug: Piperacillin in
Normalized name: piperacillin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin in combination with povidone-iodine enema (Group C, n = 25)
Study: 345198
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg aspirin (ASA)
Study: 25730053
Drug: 50 U/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 U/mL BTX‐A injection
Study: 25730053
Drug: 25 U/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 U/mL BTX‐A injection
Study: 25730053
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (50 U/mL and 25 U/mL BTX‐A)
Study: 25730053
Drug: High-concentration group
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration group (50 U/mL)
Study: 25730053
Drug: Low-concentration group
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentration group (25 U/mL)
Study: 24095604
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention regarding anxiety and satisfaction (oral and written information on safety, risks, and benefits of haemotherapy)
Study: 19699838
Drug: 113 g
Normalized name: UREA 40 g in 113 g TOPICAL GEL [Bare 40 Plus HA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 113 g serving of 90% lean beef (30 g protein)
Study: 19699838
Drug: 340 g
Normalized name: ALCOHOL 0.7 g in 340 g TOPICAL LOTION [Moxe]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 340 g serving of 90% lean beef (90 g protein)
Study: 8063021
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg acyclovir twice daily (first year)
Study: 8063021
Drug: Open-label acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label acyclovir suppressive therapy (after first year)
Study: 8063021
Drug: Suppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppressive therapy for 5 years
Study: 31286397
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose of 1 μg kg-1 followed by 0.5 μg kg-1 h-1)
Study: 31286397
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (bolus 0.08 mg kg-1 followed by a saline infusion)
Study: 31286397
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of intraoperative morphine consumption
Study: 22517036
Drug: Higher parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher parenteral amino acid intakes (4 g kg(‐1) per day)
Study: 22517036
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral amino acid intakes (3 g kg(‐1) per day)
Study: 12582020
Drug: High-dose aliretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aliretinoin (50 mg)
Study: 12582020
Drug: Low-dose aliretinoin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aliretinoin (25 mg)
Study: 9171752
Drug: High-dose bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bolus tPA (three doses of 5 mg over 30 min, then 3.5 mg/h for up to 4 h, then 0.5-1.0 mg/h)
Study: 9171752
Drug: Low-dose tPA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tPA (0.5-1.0 mg/h)
Study: 3203706
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg benazepril
Study: 3511937
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg acute treatment)
Study: 3511937
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg twice daily for 7 days chronic treatment)
Study: 3511937
Drug: Indomethacin (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (acute and chronic treatments)
Study: 29705457
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 5% lavender essential oil (2 drops)
Study: 27206122
Drug: Renin angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin angiotensin system antagonists (RASA)
Study: 27206122
Drug: All medication
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All medication classes combined
Study: 24646861
Drug: PA21 (sucroferric
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA21 (sucroferric oxyhydroxide) 1.0-3.0 g per day
Study: 24646861
Drug: Sevelamer carbonate
Normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer carbonate 4.8-14.4 g per day
Study: 24646861
Drug: PA21 maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PA21 maintenance dose
Study: 24646861
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (250 mg per day)
Study: 22226343
Drug: Inhaled loxapine
Normalized name: loxapine Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled loxapine 5 mg
Study: 22226343
Drug: Inhaled loxapine
Normalized name: loxapine Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled loxapine 10 mg
Study: 20578931
Drug: OROS methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS methylphenidate (OROS MPH) 54 mg or greater
Study: 20578931
Drug: Weight-adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-adjusted dose of OROS MPH
Study: 20578931
Drug: Absolute dose
Normalized name: Honey Absolute
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absolute dose of OROS MPH